Literature DB >> 19028980

PI3K gamma-deficient mice have reduced levels of allergen-induced eosinophilic inflammation and airway remodeling.

Dae Hyun Lim1, Jae Youn Cho, Dae Jin Song, Sang Yeub Lee, Marina Miller, David H Broide.   

Abstract

In this study, we have examined the role of phosphoinositide 3 kinase gamma (PI3Kgamma), a class Ib PI3K, in contributing to airway remodeling utilizing PI3Kgamma-deficient mice exposed to chronic allergen challenge. Wild-type (WT) mice sensitized to ovalbumin (OVA) and chronically challenged with OVA for 1 mo developed significantly increased levels of eosinophilic inflammation and airway remodeling. In contrast, PI3Kgamma-deficient mice challenged with OVA had significantly reduced numbers of bronchoalveolar lavage and peribronchial eosinophils compared with WT mice. There was no significant difference in the number of bone marrow or circulating peripheral blood eosinophils when comparing WT mice and PI3Kgamma-deficient mice, suggesting that trafficking of eosinophils into the lung was reduced in PI3Kgamma-deficient mice. PI3Kgamma-deficient and WT mice had similar levels of IL-5 and eotaxin-1. The reduced eosinophil recruitment to the airway in PI3Kgamma-deficient mice challenged with OVA was associated with significantly reduced numbers of TGF-beta1+ peribronchial cells, reduced numbers of pSmad 2/3+ airway epithelial cells, and pSmad 2/3+ peribronchial cells, as well as significantly reduced levels of peribronchial fibrosis (quantitated by trichrome staining and image analysis as well as by lung collagen levels). In addition, the area of peribronchial alpha-smooth muscle staining was significantly reduced in PI3Kgamma-deficient compared with WT mice. Overall, this study demonstrates an important role for PI3Kgamma in mediating allergen-induced eosinophilic airway inflammation and airway remodeling, suggesting that PI3Kgamma may be a novel therapeutic target in asthma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19028980      PMCID: PMC2643991          DOI: 10.1152/ajplung.90275.2008

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  33 in total

1.  Function of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration.

Authors:  T Sasaki; J Irie-Sasaki; R G Jones; A J Oliveira-dos-Santos; W L Stanford; B Bolon; A Wakeham; A Itie; D Bouchard; I Kozieradzki; N Joza; T W Mak; P S Ohashi; A Suzuki; J M Penninger
Journal:  Science       Date:  2000-02-11       Impact factor: 47.728

Review 2.  The phosphoinositide 3-kinase pathway.

Authors:  Lewis C Cantley
Journal:  Science       Date:  2002-05-31       Impact factor: 47.728

3.  Inhibition of airway remodeling in IL-5-deficient mice.

Authors:  Jae Youn Cho; Marina Miller; Kwang Je Baek; Ji Won Han; Jyothi Nayar; Sook Young Lee; Kirsti McElwain; Shauna McElwain; Stephanie Friedman; David H Broide
Journal:  J Clin Invest       Date:  2004-02       Impact factor: 14.808

4.  Involvement of PTEN in airway hyperresponsiveness and inflammation in bronchial asthma.

Authors:  Yong-Geun Kwak; Chang H Song; Ho K Yi; Pyoung H Hwang; Jong-Suk Kim; Kyung S Lee; Yong C Lee
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

5.  Phosphoinositide 3-kinase gamma is an essential amplifier of mast cell function.

Authors:  Muriel Laffargue; Ronan Calvez; Peter Finan; Alexandre Trifilieff; Maryse Barbier; Fiorella Altruda; Emilio Hirsch; Matthias P Wymann
Journal:  Immunity       Date:  2002-03       Impact factor: 31.745

6.  Defining a link with asthma in mice congenitally deficient in eosinophils.

Authors:  James J Lee; Dawn Dimina; MiMi P Macias; Sergei I Ochkur; Michael P McGarry; Katie R O'Neill; Cheryl Protheroe; Ralph Pero; Thanh Nguyen; Stephania A Cormier; Elizabeth Lenkiewicz; Dana Colbert; Lisa Rinaldi; Steven J Ackerman; Charles G Irvin; Nancy A Lee
Journal:  Science       Date:  2004-09-17       Impact factor: 47.728

Review 7.  Immunologic and inflammatory mechanisms that drive asthma progression to remodeling.

Authors:  David H Broide
Journal:  J Allergy Clin Immunol       Date:  2008-03       Impact factor: 10.793

8.  Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics.

Authors:  Patrick Flood-Page; Andrew Menzies-Gow; Simon Phipps; Sun Ying; Arun Wangoo; Mara S Ludwig; Neil Barnes; Douglas Robinson; A Barry Kay
Journal:  J Clin Invest       Date:  2003-10       Impact factor: 14.808

9.  Blockade of inflammation and airway hyperresponsiveness in immune-sensitized mice by dominant-negative phosphoinositide 3-kinase-TAT.

Authors:  Shigeharu Myou; Alan R Leff; Saori Myo; Evan Boetticher; Jiankun Tong; Angelo Y Meliton; Jie Liu; Nilda M Munoz; Xiangdong Zhu
Journal:  J Exp Med       Date:  2003-11-17       Impact factor: 14.307

10.  Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model.

Authors:  P S Foster; S P Hogan; A J Ramsay; K I Matthaei; I G Young
Journal:  J Exp Med       Date:  1996-01-01       Impact factor: 14.307

View more
  25 in total

1.  Phosphoinositide 3-kinase gamma regulates airway smooth muscle contraction by modulating calcium oscillations.

Authors:  Haihong Jiang; Peter W Abel; Myron L Toews; Caishu Deng; Thomas B Casale; Yan Xie; Yaping Tu
Journal:  J Pharmacol Exp Ther       Date:  2010-05-25       Impact factor: 4.030

Review 2.  Phosphoinositide 3-Kinase in Asthma: Novel Roles and Therapeutic Approaches.

Authors:  Edwin J Yoo; Christie A Ojiaku; Krishna Sunder; Reynold A Panettieri
Journal:  Am J Respir Cell Mol Biol       Date:  2017-06       Impact factor: 6.914

3.  Anti-Asthma Simplified Herbal Medicine Intervention-induced long-lasting tolerance to allergen exposure in an asthma model is interferon-γ, but not transforming growth factor-β dependent.

Authors:  K Srivastava; T Zhang; N Yang; H Sampson; X M Li
Journal:  Clin Exp Allergy       Date:  2010-11       Impact factor: 5.018

Review 4.  Role of phosphoinositide 3-kinase in the pathogenesis of acute pancreatitis.

Authors:  Enrico Lupia; Luca Pigozzi; Alberto Goffi; Emilio Hirsch; Giuseppe Montrucchio
Journal:  World J Gastroenterol       Date:  2014-11-07       Impact factor: 5.742

5.  Targeting phosphoinositide 3-kinase γ in airway smooth muscle cells to suppress interleukin-13-induced mouse airway hyperresponsiveness.

Authors:  Haihong Jiang; Yan Xie; Peter W Abel; Myron L Toews; Robert G Townley; Thomas B Casale; Yaping Tu
Journal:  J Pharmacol Exp Ther       Date:  2012-04-27       Impact factor: 4.030

6.  Adiponectin-deficient mice are protected against tobacco-induced inflammation and increased emphysema.

Authors:  Marina Miller; Alexa Pham; Jae Youn Cho; Peter Rosenthal; David H Broide
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-10-08       Impact factor: 5.464

Review 7.  Targeting the B-cell receptor signaling pathway in B lymphoid malignancies.

Authors:  Maike Buchner; Markus Müschen
Journal:  Curr Opin Hematol       Date:  2014-07       Impact factor: 3.284

8.  Chronic OVA allergen challenged Siglec-F deficient mice have increased mucus, remodeling, and epithelial Siglec-F ligands which are up-regulated by IL-4 and IL-13.

Authors:  Jae Youn Cho; Dae Jae Song; Alexa Pham; Peter Rosenthal; Marina Miller; Shanna Dayan; Taylor A Doherty; Ajit Varki; David H Broide
Journal:  Respir Res       Date:  2010-11-01

9.  Toll-like receptor-9 agonist inhibits airway inflammation, remodeling and hyperreactivity in mice exposed to chronic environmental tobacco smoke and allergen.

Authors:  Dae Jin Song; Myung Goo Min; Marina Miller; Jae Youn Cho; Hye Yung Yum; David H Broide
Journal:  Int Arch Allergy Immunol       Date:  2009-10-22       Impact factor: 2.749

10.  Exacerbation of allergic inflammation in mice exposed to diesel exhaust particles prior to viral infection.

Authors:  Ilona Jaspers; Patricia A Sheridan; Wenli Zhang; Luisa E Brighton; Kelly D Chason; Xiaoyang Hua; Stephen L Tilley
Journal:  Part Fibre Toxicol       Date:  2009-08-14       Impact factor: 9.400

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.